Add Formweb to your mobile device
Approved Formulary
Search results for:
rivastigmine
rivastigmine
Brand names: Exelon
| Form | Strength |
|---|---|
| CAPSULE, ORAL | 1.5 mg |
| FILM, EXTENDED RELEASE, TRANSDERMAL | 4.6 mg/24 hr; 9.5 mg/24 hr; 13.3 mg/24 hr |
Display Parasympathomimetic (Cholinergic) Agents Class:
120400
Medication comments:
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | rivastigmine (Exelon) |
| Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3) | |
| Drug(s) ⇆ disease or syndrome | cholinesterase inhibitors (AChEIs) ⇄ Syncope |
| Rationale | AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. |
| Recommendation | Avoid |
| Quality of evidence: High, Strength of Recommendation: Strong | |
Last updated: Sep. 19, 2025